Novartis agreed to use Alteogen’s Hybrozyme-based ALT-B4 enzyme platform to support subcutaneous delivery of multiple biologics, in a deal worth up to $3.2 billion. The agreement underscores continued shift by large pharma toward enabling faster, less burdensome dosing than intravenous administration. ALT-B4 (berahyaluronidase alfa) is designed to transiently break down hyaluronan in the extracellular matrix under the skin, allowing co-administered biologics to disperse and absorb more rapidly. Option rights cover development and commercialization of subcutaneous formulations across several products. AstraZeneca and GSK/Tesaro previously executed similar licensing paths for ALT-B4, reinforcing that delivery-enabling assets are becoming central to biopharma product strategy as companies seek to improve treatment convenience without changing core modalities.